The report analyzes and forecasts the gene delivery system market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of gene delivery system, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major gene delivery system companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of gene delivery system upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of gene delivery system and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global gene delivery system market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the gene delivery system market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of gene delivery system market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players operating in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the global gene delivery system market are Novartis AG, Amgen Inc., Oxford BioMedia plc, SIBIONO, Shanghai Sunway Biotech Co. Ltd., Pfizer Inc., Bayer AG, Johnson & Johnson Services Inc., Human Stem Cells Institute, and Epeius Biotechnologies Corporation.
The global gene delivery system market has been segmented as follows:
Gene Delivery System Market, by Delivery System
Gene Delivery System Market, by Application
Gene Delivery System Market, by Route of Administration
Gene Delivery System Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Gene Delivery System Market
4. Market Overview
4.1. Introduction
4.1.1. Delivery System Definition
4.2. Overview
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Global Gene Delivery System Market Analysis and Forecasts, 2017–2026
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Market Outlook
4.8. Technological Advancements in Gene Delivery Products
4.9. Regulatory Scenario
4.10. Gene Therapy Pipeline Molecules
5. Global Gene Delivery System Market Analysis and Forecasts, by Delivery System
5.1. Introduction & Definition
5.2. Key Findings
5.4. Market Value Forecast by Delivery System, 2017–2026
5.4.1. Viral Gene Delivery
5.4.1.1. Adenovirus Vector
5.4.1.2. Lentivirus Vector
5.4.1.3. Retrovirus Vector
5.4.1.4. Adeno-associated Virus Vector
5.4.1.5. Sendai Virus Vector
5.4.1.6. Herpes Simplex Virus Vector
5.4.1.7. Others
5.4.2. Non-viral Gene Delivery
5.4.2.1. Natural Organic Compounds
5.4.2.2. Physical Methods
5.4.2.3. Chemical Methods
5.4.3. Combined Hybrid Delivery System
5.5. Market Attractiveness by Delivery System
6. Global Gene Delivery System Market Analysis and Forecasts, by Application
6.1. Introduction & Definition
6.2. Key Findings
6.4. Market Value Forecast by Application, 2017–2026
6.4.1. Infectious Diseases
6.4.2. Oncology
6.4.3. Ophthalmology
6.4.4. Urology
6.4.5. Diabetes
6.4.6. CNS
6.4.7. Others
6.5. Market Attractiveness by Application
7. Global Gene Delivery System Market Analysis and Forecasts, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings
7.4. Market Value Forecast by Route of Administration, 2017–2026
7.4.1. Oral
7.4.2. Injectable
7.4.3. Inhalation
7.4.4. Transdermal
7.4.5. Ocular
7.4.6. Nasal
7.4.7. Topical
7.5. Market Attractiveness by Route of Administration
8. Global Gene Delivery System Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness by Region
9. North America Gene Delivery System Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast by Delivery System, 2017–2026
9.2.1. Viral Gene Delivery
9.2.1.1. Adenovirus Vector
9.2.1.2. Lentivirus Vector
9.2.1.3. Retrovirus Vector
9.2.1.4. Adeno-associated Virus Vector
9.2.1.5. Sendai Virus Vector
9.2.1.6. Herpes Simplex Virus Vector
9.2.1.7. Others
9.2.2. Non-viral Gene Delivery
9.2.2.1. Natural Organic Compounds
9.2.2.2. Physical Methods
9.2.2.3. Chemical Methods
9.2.3. Combined Hybrid Delivery System
9.3. Market Value Forecast by Application, 2017–2026
9.3.1. Infectious Diseases
9.3.2. Oncology
9.3.3. Ophthalmology
9.3.4. Urology
9.3.5. Diabetes
9.3.6. CNS
9.3.7. Others
9.4. Market Value Forecast by Route of Administration, 2017–2026
9.4.1. Oral
9.4.2. Injectable
9.4.3. Inhalation
9.4.4. Transdermal
9.4.5. Ocular
9.4.6. Nasal
9.4.7. Topical
9.5. Market Value Forecast by Country, 2017–2026
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. by Delivery System
9.6.2. by Application
9.6.3. by Route of Administration
9.6.4. by Country
10. Europe Gene Delivery System Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast by Delivery System, 2017–2026
10.2.1. Viral Gene Delivery
10.2.1.1. Adenovirus Vector
10.2.1.2. Lentivirus Vector
10.2.1.3. Retrovirus Vector
10.2.1.4. Adeno-associated Virus Vector
10.2.1.5. Sendai Virus Vector
10.2.1.6. Herpes Simplex Virus Vector
10.2.1.7. Others
10.2.2. Non-viral Gene Delivery
10.2.2.1. Natural Organic Compounds
10.2.2.2. Physical Methods
10.2.2.3. Chemical Methods
10.2.3. Combined Hybrid Delivery System
10.3.Market Value Forecast by Application, 2017–2026
10.3.1. Infectious Diseases
10.3.2. Oncology
10.3.3. Ophthalmology
10.3.4. Urology
10.3.5. Diabetes
10.3.6. CNS
10.3.7. Others
10.4.Market Value Forecast by Route of Administration, 2017–2026
10.4.1. Oral
10.4.2. Injectable
10.4.3. Inhalation
10.4.4. Transdermal
10.4.5. Ocular
10.4.6. Nasal
10.4.7. Topical
10.5.Market Value Forecast by Country/Sub-region, 2017–2026
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6.Market Attractiveness Analysis
10.6.1. by Delivery System
10.6.2. by Application
10.6.3. by Route of Administration
10.6.4. by Country/Sub-region
11. Asia Pacific Gene Delivery System Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast by Delivery System, 2017–2026
11.2.1. Viral Gene Delivery
11.2.1.1. Adenovirus Vector
11.2.1.2. Lentivirus Vector
11.2.1.3. Retrovirus Vector
11.2.1.4. Adeno-associated Virus Vector
11.2.1.5. Sendai Virus Vector
11.2.1.6. Herpes Simplex Virus Vector
11.2.1.7. Others
11.2.2. Non-viral Gene Delivery
11.2.2.1. Natural Organic Compounds
11.2.2.2. Physical Methods
11.2.2.3. Chemical Methods
11.2.3. Combined Hybrid Delivery System
11.3.Market Value Forecast by Application, 2017–2026
11.3.1. Infectious Diseases
11.3.2. Oncology
11.3.3. Ophthalmology
11.3.4. Urology
11.3.5. Diabetes
11.3.6. CNS
11.3.7. Others
11.4.Market Value Forecast by Route of Administration, 2017–2026
11.4.1. Oral
11.4.2. Injectable
11.4.3. Inhalation
11.4.4. Transdermal
11.4.5. Ocular
11.4.6. Nasal
11.4.7. Topical
11.5.Market Value Forecast by Country/Sub-region, 2017–2026
11.5.1. Japan
11.5.2. China
11.5.3. India
11.5.4. Australia and New Zealand
11.5.5. Rest of Asia Pacific
11.6.Market Attractiveness Analysis
11.6.1. by Delivery System
11.6.2. by Application
11.6.3. by Route of Administration
11.6.4. by Country
12. Latin America Gene Delivery System Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast by Delivery System, 2017–2026
12.2.1. Viral Gene Delivery
12.2.1.1. Adenovirus Vector
12.2.1.2. Lentivirus Vector
12.2.1.3. Retrovirus Vector
12.2.1.4. Adeno-associated Virus Vector
12.2.1.5. Sendai Virus Vector
12.2.1.6. Herpes Simplex Virus Vector
12.2.1.7. Others
12.2.2. Non-viral Gene Delivery
12.2.2.1. Natural Organic Compounds
12.2.2.2. Physical Methods
12.2.2.3. Chemical Methods
12.2.3. Combined Hybrid Delivery System
12.3.Market Value Forecast by Application, 2017–2026
12.3.1. Infectious Diseases
12.3.2. Oncology
12.3.3. Ophthalmology
12.3.4. Urology
12.3.5. Diabetes
12.3.6. CNS
12.3.7. Others
12.4.Market Value Forecast by Route of Administration, 2017–2026
12.4.1. Oral
12.4.2. Injectable
12.4.3. Inhalation
12.4.4. Transdermal
12.4.5. Ocular
12.4.6. Nasal
12.4.7. Topical
12.5.Market Value Forecast by Country/Sub-region, 2017–2026
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6.Market Attractiveness Analysis
12.6.1. by Delivery System
12.6.2. by Application
12.6.3. by Route of Administration
12.6.4. by Country/Sub-region
13. Middle East & Africa Gene Delivery System Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast by Delivery System, 2017–2026
13.2.1. Viral Gene Delivery
13.2.1.1. Adenovirus Vector
13.2.1.2. Lentivirus Vector
13.2.1.3. Retrovirus Vector
13.2.1.4. Adeno-associated Virus Vector
13.2.1.5. Sendai Virus Vector
13.2.1.6. Herpes Simplex Virus Vector
13.2.1.7. Others
13.2.2. Non-viral Gene Delivery
13.2.2.1. Natural Organic Compounds
13.2.2.2. Physical Methods
13.2.2.3. Chemical Methods
13.2.3. Combined Hybrid Delivery System
13.3.Market Value Forecast by Application, 2017–2026
13.3.1. Infectious Diseases
13.3.2. Oncology
13.3.3. Ophthalmology
13.3.4. Urology
13.3.5. Diabetes
13.3.6. CNS
13.3.7. Others
13.4.Market Value Forecast by Route of Administration, 2017–2026
13.4.1. Oral
13.4.2. Injectable
13.4.3. Inhalation
13.4.4. Transdermal
13.4.5. Ocular
13.4.6. Nasal
13.4.7. Topical
13.5.Market Value Forecast by Country/Sub-region, 2017–2026
13.5.1. South Africa
13.5.2. UAE
13.5.3. Saudi Arabia
13.5.4. Rest of Middle East & Africa
13.6.Market Attractiveness Analysis
13.6.1. by Delivery System
13.6.2. by Application
13.6.3. by Route of Administration
13.6.4. by Country/Sub-region
14. Competition Landscape
14.1.Market Player – Competition Matrix (by Tier and Size of Companies)
14.2.Market Share Analysis by Company (2016)
14.3.Company Profiles (Overview, Financials, Recent Developments, Strategy)
14.3.1. Novartis AG
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Amgen Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Oxford BioMedia plc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. SIBIONO
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Shanghai Sunway Biotech Co. Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Pfizer Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Bayer AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Johnson & Johnson Services Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Human Stem Cells Institute
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Epeius Biotechnologies Corporation
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers